Credit Agricole
AIMT

Credit Agricole’s Aimmune Therapeutics AIMT Stock Holding History

Credit Agricole’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-410,483
Closed -$8.99M – 1656
2017
Q1 		$8.99M Buy
+410,483
New +$8.42M 0.03% 582

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Credit Agricole's AIMT Position: Q2 2017 in Review

Credit Agricole sold out of Aimmune Therapeutics (AIMT) in Q2 2017, closing a stake of 410,483 shares — an estimated $8.99M sold.

Credit Agricole first reported a position in AIMT in Q1 2017 and held it in 1 quarter. The position peaked at $8.99M in Q1 2017. 96 funds tracked by Wall St. Rank hold AIMT as of Q2 2017.

  • Credit Agricole reported no remaining Aimmune Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Credit Agricole sold 410,483 Aimmune Therapeutics shares in Q2 2017, an estimated $8.99M.
  • Credit Agricole first reported a position in Aimmune Therapeutics in Q1 2017 and held it in 1 quarter.
  • Credit Agricole's Aimmune Therapeutics position peaked at $8.99M in Q1 2017.
  • 96 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2017.

Based on Credit Agricole's 13F filing for Q2 2017, filed 14 Aug 2017.